GSK-1614235/GSK-2330672

N/A

Report date: 2023/12/01 18:05:31

Base Information

Drug NameGSK-1614235/GSK-2330672
Drug Alias NameGSK 1614235/GSK 2330672GSK 2330672/GSK 1614235GSK-2330672 and GSK-1614235GSK-2330672/GSK-1614235GSK-1614235 and GSK-2330672 +[6] 
ClassificationSmall molecules
Mechanisms of ActionIleal bile acid transporter inhibitorsSodium/glucose cotransporter 1 inhibitors
TargetsIleal bile acid transporterSodium/glucose cotransporter 1
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes LinerixibatMizagliflozin
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A